The Relationship between Timing of Initiation on a Glucagon-Like Peptide-1 Receptor Agonist and HbA1c among Patients with Type 2 Diabetes

被引：0
|
作者：
Malik, Raleigh E.
Mody, Reema
Lage, Maureen J.
Boye, Kristina
机构：
来源：
DIABETES | 2020年 / 69卷
关键词：
D O I：
10.2337/db20-938-P
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
938-P
引用
收藏
页数：2
相关论文
共 50 条
  • [31] Glucagon-like peptide-1 receptor
    Krashes, Michael
    CURRENT BIOLOGY, 2024, 34 (23) : R1163 - R1164
  • [32] The Role of Glucagon-Like Peptide-1 Receptor Agonists in Type 2 Diabetes in Asia
    Lu, Ju-Ming
    ADVANCES IN THERAPY, 2019, 36 (04) : 798 - 805
  • [33] Dual-acting peptide with prolonged glucagon-like peptide-1 receptor agonist and glucagon receptor antagonist activity for the treatment of type 2 diabetes
    Claus, Thomas H.
    Pan, Clark Q.
    Buxton, Joanne M.
    Yang, Ling
    Reynolds, Jennifer C.
    Barucci, Nicole
    Burns, Michael
    Ortiz, Astrid A.
    Roczniak, Steve
    Livingston, James N.
    Clairmont, Kevin B.
    Whelan, James P.
    JOURNAL OF ENDOCRINOLOGY, 2007, 192 (02) : 371 - 380
  • [34] Real-world use of glucagon-like peptide-1 receptor agonists in youth with type 2 diabetes is associated with short-term improvements in HbA1c
    Samuels, Stephanie L.
    Chajecki, Anastasia
    Hu, Pamela
    Kayser, Michelle
    Weyman, Kate
    Pan, Bernard
    Brown, Elizabeth A.
    Van Name, Michelle
    Wolf, Risa M.
    DIABETES OBESITY & METABOLISM, 2024, 26 (04): : 1305 - 1313
  • [35] Glucagon-like peptide-1 receptor agonists decreases albuminuria in overweight patients with type 2 diabetes
    Bulum, T.
    Blaslov, K.
    Tomic, M.
    Duvnjak, L.
    DIABETOLOGIA, 2015, 58 : S532 - S533
  • [36] Glucagon-Like Peptide-1 Receptor Agonists and Liver Outcomes in Patients With MASLD and Type 2 Diabetes
    Kuo, Chia-Chih
    Chuang, Min-Hsiang
    Li, Chun-Hsien
    Tsai, Ya-Wen
    Huang, Po-Yu
    Kuo, Hsing-Tao
    Lai, Chih-Cheng
    ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2025, 61 (07) : 1163 - 1174
  • [37] Racial, Ethnic, and Socioeconomic Inequities in Glucagon-Like Peptide-1 Receptor Agonist Use Among Patients With Diabetes in the US
    Eberly, Lauren A.
    Yang, Lin
    Essien, Utibe R.
    Eneanya, Nwamaka D.
    Julien, Howard M.
    Luo, Jing
    Nathan, Ashwin S.
    Khatana, Sameed Ahmed M.
    Dayoub, Elias J.
    Fanaroff, Alexander C.
    Giri, Jay
    Groeneveld, Peter W.
    Adusumalli, Srinath
    JAMA HEALTH FORUM, 2021, 2 (12): : E214182
  • [38] HBA1C CONTROL AND COST-EFFECTIVENESS IN PATIENTS WITH TYPE 2 DIABETES MELLITUS INITIATED ON CANAGLIFLOZIN OR A GLUCAGON-LIKE PEPTIDE 1 RECEPTOR AGONIST IN A REAL-WORLD SETTING
    Wysham, Carol H.
    Pilon, Dominic
    Ingham, Mike
    Lafeuille, Marie-Helene
    Emond, Bruno
    Kamstra, Rhiannon
    Pfeifer, Michael
    Lefebvre, Patrick
    ENDOCRINE PRACTICE, 2018, 24 (03) : 273 - 287
  • [39] Glucagon-like peptide-1 therapy for youth with type 2 diabetes
    Cho, Young Min
    JOURNAL OF DIABETES INVESTIGATION, 2023, 14 (03) : 362 - 363
  • [40] FUNCTIONAL FORM OF THE RELATIONSHIP BETWEEN ADHERENCE TO GLUCAGON-LIKE PEPTIDE-1 RECEPTOR AGONIST THERAPY AND MEDICAL HEALTH CARE COSTS AMONG PATIENTS WITH TYPE 2 DIABETES IN THE UNITED STATES
    Johnston, S.
    Cappell, K. A.
    Nelson, J.
    Chu, B.
    Nguyen, H.
    VALUE IN HEALTH, 2016, 19 (03) : A205 - A205
12345